Cetuximab inhibits cisplatin-induced activation of EGFR signaling in esophageal squamous cell carcinoma
Tóm tắt
Từ khóa
Tài liệu tham khảo
Darling, 2009, The role of lymphadenectomy in esophageal cancer, J Surg Oncol, 99, 189, 10.1002/jso.21209
Kranzfelder, 2011, Meta-analysis of neoadjuvant treatment modalities and definitive non-surgical therapy for oesophageal squamous cell cancer, Br J Surg, 98, 768, 10.1002/bjs.7455
Chiu, 2005, Multicenter prospective randomized trial comparing standard esophagectomy with chemoradiotherapy for treatment of squamous esophageal cancer: early results from the Chinese University Research Group for Esophageal Cancer (CURE), J Gastrointest Surg, 9, 794, 10.1016/j.gassur.2005.05.005
Bleiberg, 1997, Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer, Eur J Cancer, 33, 1216, 10.1016/S0959-8049(97)00088-9
Polee, 2001, Phase II study of the combination cisplatin, etoposide, 5-fluorouracil and folinic acid in patients with advanced squamous cell carcinoma of the esophagus, Anticancer Drugs, 12, 513, 10.1097/00001813-200107000-00004
Hanawa, 2006, EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus, Int J Cancer, 118, 1173, 10.1002/ijc.21454
Mendelsohn, 2000, The EGF receptor family as targets for cancer therapy, Oncogene, 19, 6550, 10.1038/sj.onc.1204082
Vermorken, 2007, Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy, J Clin Oncol, 25, 2171, 10.1200/JCO.2006.06.7447
Sobrero, 2008, EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer, J Clin Oncol, 26, 2311, 10.1200/JCO.2007.13.1193
Vincenzi, 2008, The biological properties of cetuximab, Crit Rev Oncol Hematol, 68, 93, 10.1016/j.critrevonc.2008.07.006
Vermorken, 2008, Platinum-based chemotherapy plus cetuximab in head and neck cancer, N Engl J Med, 359, 1116, 10.1056/NEJMoa0802656
Ilson, 2008, Esophageal cancer chemotherapy: recent advances, Gastrointest Cancer Res, 2, 85
Cascone, 2008, Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells, J Cell Physiol, 216, 698, 10.1002/jcp.21444
Meira, 2009, Combination of cetuximab with chemoradiation, trastuzumab or MAPK inhibitors: mechanisms of sensitisation of cervical cancer cells, Br J Cancer, 101, 782, 10.1038/sj.bjc.6605216
Tomblyn, 2012, Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414), J Thorac Oncol, 7, 906, 10.1097/JTO.0b013e31824c7bed
Lee, 2013, Preoperative cetuximab, irinotecan, cisplatin, and radiation therapy for patients with locally advanced esophageal cancer, Oncologist, 18, 281, 10.1634/theoncologist.2012-0208
Meng, 2013, Cetuximab in combination with chemoradiotherapy in Chinese patients with non-resectable, locally advanced esophageal squamous cell carcinoma: a prospective, multicenter phase II trail, Radiother Oncol, 109, 275, 10.1016/j.radonc.2013.09.008
Crosby, 2013, Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial, Lancet Oncol, 14, 627, 10.1016/S1470-2045(13)70136-0
Lennerz, 2011, MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib, J Clin Oncol, 29, 4803, 10.1200/JCO.2011.35.4928